SARASOTA, Fla., Feb. 21, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTCBB:DNAG) today announced that Ellipsis Biotherapeutics, Inc. will complete a record quarter of revenue generation from high volume SNP genotyping. A significant portion of the revenue came from four contracts, including a major American university, two United Kingdom academic research groups, and one Toronto based academic hospital program. Ellipsis, acquired by the Company in November 2005, conducts SNP genotyping using state-of-the-art technologies. These include single-base primer extension platforms from Beckman Coulter, Inc. and the GoldenGate(tm) platform from Illumina, Inc. With a choice of platforms and scales for performing work, Ellipsis supports companies through the entire scope of their genotyping efforts. Projects include both high throughput screening of multiple samples as well as finer mapping to clarify associations of genetic predisposition in a variety of human diseases.
"Our goal is to deliver the highest quality SNP genotyping services to the marketplace, including project development, ongoing scientific advice and data analysis and interpretation," commented Dr. Laurence Rubin, founder of Ellipsis. "Ellipsis has completed these projects on schedule and within budget. Our services have been instrumental in helping scientists publish their work in respected scientific journals. In addition to completing large volume contract services for a variety of projects, we are participating in novel research programs, which has always been part of the company's focus," he added.
"We are extremely pleased that Ellipsis Biotherapeutics has met its first major milestone and has done it with better than budgeted goals and objectives. We expect that Ellipsis will continue to contribute to our revenue growth and assist our core pursuit of pharmaceuticals and diagnostics," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc.
For further information on genotyping and other DNA services, please contact Ellipsis Biotherapeutics at (416) 586-0947.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company for additional forensics work. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. The Company also performs contract genotyping and other DNA services through its Ellipsis Biotherapeutics group in Toronto, Canada.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.